Spectrum Pharma (SPPI) Reports In-Line Q2 EPS

Spectrum Pharma (NASDAQ: SPPI) reported Q2 EPS of ($0.25), in-line with the analyst estimate of ($0.25).

The company ended the quarter with cash, cash equivalents, and marketable securities of $158.8 million.

“Momentum continues to build with poziotinib and the submission of the NDA later this year is our top corporate priority,” said Joe Turgeon, President and CEO of Spectrum Pharmaceuticals. “We are also seeking clarification on the recent CRL for ROLONTIS and are planning to have a Type A meeting with the FDA as soon as possible.”

For earnings history and earnings-related data on Spectrum Pharma (SPPI) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Vivos Therapeutics posts 35% revenue gain but widens net loss
• Hydrofarm Holdings Group, Inc. (HYFM) Misses Q2 EPS by 134c